Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).

Détails

Ressource 1Télécharger: 17990150.pdf (314.32 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_3AABA6321E98
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
Périodique
Swiss medical weekly
Auteur⸱e⸱s
Ulrich S., Speich R., Domenighetti G., Geiser T., Aubert J.D., Rochat T., Huber L., Treder U., Fischler M.
ISSN
1424-7860 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
20/10/2007
Peer-reviewed
Oui
Volume
137
Numéro
41-42
Pages
573-580
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
we performed an open-label national study to evaluate the effects of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (CTEPH).
fifteen patients with CTEPH not eligible or waiting for surgery were enrolled. The primary endpoint was the change in pulmonary vascular resistance (PVR). Secondary endpoints included quality of life (measured by the Minnesota living with heart failure questionnaire, MLHF), 6 minute walk distance (6MWD), World Health Organization (WHO) functional class, Borg dyspnoea scale, plasma endothelin, serum values of disease severity such as uric acid, N-terminal-pro brain natriuretic peptide (NTproBNP), C-reactive protein measured by a highly sensitive method (CRPs) and other serum and haemodynamic parameters.
after six months of treatment with bosentan, the PVR decreased from 852 (319) to 657(249) dyn*s*m-5 (p = 0.02). Quality of life considerably improved from a mean total score of 48(14) to 35(17) (p = 0.003) with improvements in the physical (from 25(5) to 17(7)) and emotional (from 11(6) to 6(5)) subscores (p = 0.005 and 0.011), respectively. The 6MWD improved from 389(78) to 443(79) meters (p = 0.005). 4 patients (27%) improved and 11 patients (73%) maintained their WHO class with no deterioration during the six months of bosentan treatment (p = 0.02). Uric acid serum levels declined from 525(145) to 453(151) micromol/l (p = 0.006), NTproBNP and CRPs declined insignificantly. Endothelin serum levels increased from 4.3(1.5) to 5.9(2.2) pg/ml (p = 0.025). Patients tolerated the treatment well, and there were no severe adverse events or deaths.
this open-label study suggests a beneficial effect of bosentan therapy not only on pulmonary haemodynamics, but also on quality of life and exercise capacity for patients with severe CTEPH.

Mots-clé
Aged, Antihypertensive Agents/therapeutic use, Chronic Disease, Endothelin Receptor Antagonists, Exercise Tolerance, Female, Health Status Indicators, Hemodynamics, Humans, Hypertension, Pulmonary/drug therapy, Hypertension, Pulmonary/physiopathology, Male, Pulmonary Embolism/drug therapy, Pulmonary Embolism/physiopathology, Quality of Life, Severity of Illness Index, Sulfonamides/therapeutic use
Pubmed
Web of science
Création de la notice
21/01/2008 12:54
Dernière modification de la notice
20/08/2019 13:30
Données d'usage